 Antibodies, Bispecific
"Antibodies, Bispecific" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies, often monoclonal, in which the two antigen-binding sites are specific for separate ANTIGENIC DETERMINANTS. They are artificial antibodies produced by chemical crosslinking, fusion of HYBRIDOMA cells, or by molecular genetic techniques. They function as the main mediators of targeted cellular cytotoxicity and have been shown to be efficient in the targeting of drugs, toxins, radiolabeled haptens, and effector cells to diseased tissue, primarily tumors.
| Descriptor ID |
D018033
|
| MeSH Number(s) |
D12.776.124.486.485.114.125 D12.776.124.790.651.114.134 D12.776.377.715.548.114.134
|
| Concept/Terms |
Antibodies, Bispecific- Antibodies, Bispecific
- Bispecific Antibodies
- Bifunctional Antibodies
- Antibodies, Bifunctional
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Bispecific".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Bispecific".
This graph shows the total number of publications written about "Antibodies, Bispecific" by people in this website by year, and whether "Antibodies, Bispecific" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 | | 2005 | 1 | 0 | 1 | | 2012 | 0 | 1 | 1 | | 2013 | 2 | 1 | 3 | | 2014 | 1 | 0 | 1 | | 2015 | 1 | 0 | 1 | | 2016 | 1 | 0 | 1 | | 2018 | 3 | 0 | 3 | | 2019 | 2 | 1 | 3 | | 2020 | 3 | 0 | 3 | | 2021 | 5 | 0 | 5 | | 2022 | 0 | 2 | 2 | | 2023 | 5 | 0 | 5 | | 2024 | 10 | 1 | 11 | | 2025 | 9 | 1 | 10 | | 2026 | 5 | 3 | 8 |
To return to the timeline, click here.
Below are the most recent publications written about "Antibodies, Bispecific" by people in Profiles.
-
Bock AM, Feng L, Chauhan A, Falchi L, Merryman R, Godbole S, Thiruvengadam SK, Jallouk AP, Major A, D'Angelo C, Ayers A, Baron K, Farahat OM, Shouse G, Danilov A, Bair S, Lunning M, Bhaskar S, Herrera AF, Sawalha Y, Flowers CR, Crombie JL, Salles G, Epperla N, Ahmed S. Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab. Blood Adv. 2026 Aug 25; 10(16):5496-5504.
-
Budde LE, Kamdar M, Assouline SE, Chavez JC, Ghosh N, Ollila TA, Hodson DJ, Modi D, Bastos-Oreiro M, Naik SG, Nakhoda SK, Lee Batlevi C, Wang J, Makadia S, Kwan A, Penuel E, Jing J, Wu H, Ead W, Pham S, To I, Wei MC, Wang ML. Mosunetuzumab plus polatuzumab vedotin for relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study. Blood. 2026 Aug 06; 148(6):682-692.
-
Keller AL, Dennis KA, Ohlstrom DJ, Parzych SE, Walker ZJ, Novak AJ, Pham-Danis C, Medha TN, Rahkola JT, Boorgula MP, Kohler ME, Sherbenou DW. Multiple Myeloma Cells Resistant to T-cell Therapies Exhibit a CD45+ Immunoevasive Phenotype. Cancer Immunol Res. 2026 Aug 04; 14(8):1307-1321.
-
Kamdar M, Bartlett NL. From breakthroughs to blueprints: evolving evidence and future directions in relapsed and refractory large B-cell lymphoma. Blood. 2026 Jun 11; 147(24):2879-2894.
-
Major A, Ma E, Masaquel A, Tsang M, Di M, Kaur S, Pophali P, Werner S, Bungay R, Latrémouille-Viau D, Guerin A, Reyes C, Wu M, Cassoli L, Torka P. Patient-reported time toxicity with bispecific antibody therapies in relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma. Oncologist. 2026 Jun 06; 31(7).
-
Duffy JT, Martin-Regalado A, Haupt BE, Pogue JR, Thakur A, Cota MF, Zannikou M, Misener S, Krymskaya VP, McCortney K, Miska J, Horbinski C, Simberg D, Lesniak MS, James CD, Stupp R, Balyasnikova IV. Fully Humanized Bispecific T Cell Engager Shows Potent Activity in Central Nervous System and Peripheral Tumors. Adv Sci (Weinh). 2026 Jun; 13(35):e22391.
-
Rhodes EY, Xia JL, de Carlo Forest TE, Manoharan N, Palestine AG, Reddy AK. Hypertensive Anterior Uveitis Following Intravitreal Faricimab. Ocul Immunol Inflamm. 2026 May; 34(4):852-857.
-
Park JC, Berz D, Sharma MR, Malhotra J, Tolcher AW, Hauke RJ, Call JA, Hamm JT, Sanborn RE, Haas NB, Tsai F, Adkins DR, Camidge DR, Spira AI, Senne L, Kalabus J, O'Neill B, Kinkead H, Garcia J, Massarelli E. Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors. Cancer Res Commun. 2026 02 01; 6(2):374-382.
-
Buckner TW, Carpenter SL, Daoud N, Kempton CL, Lee L, Malec L, McLean TW, Morton P, O'Neill C, Staber JM, Wang M, Croteau SE, Recht M. Safety and Effectiveness of Emicizumab in People With Haemophilia A Enrolled in the ATHN 7 Haemophilia Natural History Study. Haemophilia. 2026 Jan-Feb; 32(1):63-70.
-
Wang J, Huang X, Shi Q, Swingle KL, Hamilton AG, Gong N, Mitchell MJ. Drug-loaded bispecific T cell nanoengager overcomes T cell exhaustion for potent cancer immunotherapy. Proc Natl Acad Sci U S A. 2025 Nov 11; 122(45):e2409564122.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|